Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
landgren
Aug 26, 2024, 21:33 |
Blog
C. Ola Landgren: Lots of new data at the Hematology Society of Taiwan
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader…
Jul 25, 2024, 14:07 |
Insight
Learn how Carl Ola Landgren is creating a risk profile to personalize myeloma care - HealthTree Foundation
HealthTree Foundation shared on X: "Learn how Dr. C. Ola Landgren and his colleagues at…
Jul 4, 2024, 03:09 |
Blog
C. Ola Landgren: Highlights in Multiple Myeloma From ASCO and EHA 2024
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader…
Jun 22, 2024, 04:41 |
Insight
C. Ola Landgren: How Quadruplet Therapy Is Changing the Myeloma Treatment Landscape
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader…
Jun 13, 2024, 05:46 |
Societies
Carl Ola Landgren: Getting ready with Mohamad Mohty for tomorrow’s opening session at EHA2024
Carl Ola Landgren shared on X: "Getting ready together with Mohamad Mohty for tomorrow’s opening…
Jun 4, 2024, 16:31 |
Societies
Just presented at ASCO24: IMROZ results by C. Ola Landgren - ASCO
ASCO shared a post on X: “Just presented at American Society of Clinical Oncology 2024…
May 26, 2024, 14:20 |
Blog
C. Ola Landgren on Quadruple Therapies and the Future of Multiple Myeloma Treatment
Sylvester researcher C. Ola Landgren will present an overview of new studies and the state…
Apr 26, 2024, 14:15 |
Drugs
Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker
Apr 25, 2024, 21:33 |
Blog
C. Ola Landgren: It was an honor to present the EVIDENCE meta-analysis at ODAC
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader…
Apr 14, 2024, 12:56 |
Insight
Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs
Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared…
1
2
3
All:
30
Posts:
1 - 10
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube